ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4

被引：2
|
作者：
Heerspink, Hiddo L.
Sattar, Naveed
Pavo, Imre
Haupt, Axel
Duffin, Kevin L.
Yang, Zhengyu
Wiese, Russell
Tuttle, Katherine R.
Cherney, David
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-17-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [21] COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIA
    Bogdanovic, M.
    Mihajlovic, J.
    Fournier, M.
    VALUE IN HEALTH, 2018, 21 : S133 - S133
  • [22] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with T2D and CV risk (SURPASS-4)
    Kahn, S.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Hemmingway, A.
    Wiese, R. J.
    Pearson, E. R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [23] Tirzepatide reduces serum triglyceride concentrations irrespective of concomitant fibrate use in SURPASS-4 participants with type 2 diabetes at high cardiovascular risk
    Varkonyi, T.
    Del Prato, S.
    Pavo, I.
    Nicolay, C.
    Wiese, R. J.
    Kahn, S. E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S305 - S305
  • [24] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Kovatchev, Boris
    Meng, Zhaoling
    Cali, Anna M. G.
    Perfetti, Riccardo
    Breton, Marc D.
    DIABETES THERAPY, 2020, 11 (06) : 1293 - 1302
  • [25] Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes
    Boris Kovatchev
    Zhaoling Meng
    Anna M. G. Cali
    Riccardo Perfetti
    Marc D. Breton
    Diabetes Therapy, 2020, 11 : 1293 - 1302
  • [26] Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Aronson, Ronnie
    DIABETES, 2017, 66 : A272 - A272
  • [27] Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
    Del Prato, Stefano
    Kahn, Steven E.
    Pavo, Imre
    Weerakkody, Govinda J.
    Yang, Zhengyu
    Doupis, John
    Aizenberg, Diego
    Wynne, Alan G.
    Riesmeyer, Jeffrey S.
    Heine, Robert J.
    Wiese, Russell J.
    LANCET, 2021, 398 (10313): : 1811 - 1824
  • [28] The efficacy of switching from Insulin Glargine 100 U/mL (Gla-100) to Insulin Glargine 300 U/mL (Gla-300) in patients with type 2 diabetes mellitus
    Yang, K. -H.
    Tseng, C. -T.
    Chen, L. -C.
    Chen, P. -C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 310 - 310
  • [29] Lower hypoglycaemia rates with insulin glargine 300 U/ml vs insulin degludec 100 U/ml in insulin-naive adults with type 2 diabetes: the BRIGHT randomised trial
    Bolli, G. B.
    Cheng, A.
    Bosnyak, Z.
    Boelle-Le Corfec, E.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Rosenstock, J.
    DIABETOLOGIA, 2018, 61 : S442 - S442
  • [30] Is Hypoglycemia a Modifiable Patient Risk in Type 2 Diabetes? A Pooled Analysis of Insulin Glargine 300U/mL (Gla-300) vs. 100U/mL (Gla-100) Trials
    Rosenstock, Julio
    Zhang, Quanwu
    Gerrits, Charles
    Liao, Laura
    Chew, Paul
    DIABETES, 2015, 64 : A110 - A110
12345